Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode

Novartis International AG / Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• TRANSITION shows that Entresto can be safely initiated shortly after an acute heart failure episode, both in the hospital and in an out-patient setting and in a wide range of stabilized patients[1]
   

83% of chronic heart failure patients are hospitalized at least once due to an acute heart failure episode[2]
 

Outlook for patients in first 30 days following hospitalization is poor, with one in four re-admitted[3] during this vulnerable period and up to 10% likely to die[4]
 

Entresto has been proven in the landmark PARADIGM-HF study to be superior to enalapril in reducing CV mortality, HF hospitalization and 30-day hospital readmission in heart failure patients with reduced ejection fraction[5],[6]

 

Basel, August 25, 2018 - Data from the TRANSITION study presented today at the European Society of Cardiology (ESC) Congress in Munich, Germany has shown that Entresto^® (sacubitril/valsartan) can be initiated early and safely in a wide range of heart failure patients with reduced ejection fraction (HFrEF) who have been stabilized after hospitalization due to an acute heart failure episode[1]. Patients involved in the study included those with no prior experience of Entresto or conventional HF therapies, as well as those with prior experience of conventional HF therapies[1].

About half of all heart failure patients have reduced ejection fraction[7], and optimizing treatment for these patients according to guidelines is critical to reduce the likelihood of another acute episode or dying[8]. However, there is often hesitancy to initiate a new treatment after a hospitalization as these patients are considered 'vulnerable' and unable to tolerate changes in their medication.

"In the weeks following an episode of acute heart failure, patients are very vulnerable and face a high risk of re-hospitalization and death," said Prof. Rolf Wachter, University Hospital Leipzig, Germany and study investigator. "The PARADIGM-HF study showed that sacubitril/valsartan reduces heart failure-related hospitalizations, re-hospitalization and death. TRANSITION shows that sacubitril/valsartan can be initiated early and safely in patients shortly after an acute heart failure episode, providing physicians with added confidence to optimize their care with innovative medicines in heart failure treatment."